Founded in 2019, Altay Therapeutics develops small molecule drugs for a wide range of diseases, with a focus on chronic liver diseases like liver fibrosis and liver cancer.

The company’s small molecules have potent inhibitor activity against disease-causing transcription factors by disrupting their association with DNA, and according to the company have shown exceptional results in several animal models for fibrotic diseases and several cancers.

The company’s initial focus is on finding treatments for chronic inflammatory liver diseases such as NASH and liver cancer and it expects to nominate a lead drug for liver diseases by Q1 of 2021. In addition, pre-clinical studies for prostate cancer and Ewings Sarcoma are said to show great efficacy and the company expects to nominate a lead for its prostate cancer program by Q2 of 2021.

Approach: Platform to identify Novel small molecules inhibitors of transcription factors.

Potential Indications: Chronic inflammatory diseases, Chronic liver diseases, Fibrosis, NASH, Liver cancer, Rheumatoid arthritis, Ulcerative colitis, Prostate cancer, Ewings sarcoma.

Stage: Pre-clinical

The company’s a team that has more than 70 years of small molecule drug development experience, and includes co-founder Dr. Osman Ozes, who led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis.

Subscribe for alerts on new companies featured on Startups.Bio

• Archon BiosciencesNovember 20, 2024
  Archon Biosciences is a biotech company pioneering computationally designed ‘Antibody Cages’ to… Read more: Archon Biosciences
• Cytospire TherapeuticsNovember 13, 2024
  Founded in 2023, Cytospire Therapeutics is developing a portfolio of next-generation immune… Read more: Cytospire Therapeutics
• This Week in Biotech Venture CapitalNovember 4, 2024
  The biotech sector continues to see a strong flow of new venture… Read more: This Week in Biotech Venture Capital
• THRONCATOctober 30, 2024
  THRONCAT is a new startup that aims to transform the field of… Read more: THRONCAT
• Roundup of recent venture funding roundsOctober 21, 2024
  The biotechnology sector is advancing rapidly, fueled by significant venture capital investments… Read more: Roundup of recent venture funding rounds
• Analona TherapeuticsOctober 21, 2024
  Founded in 2024, Analona Therapeutics is a biotech company located in Denmark… Read more: Analona Therapeutics